No Data
Saisheng Pharmaceutical (300485.SZ): Subsidiary dapagliflozin API marketing application accepted
On December 23, the company Beijing Science Sun Pharmaceutical (300485.SZ) announced that its subsidiary, Beijing Sai'er Biopharmaceutical Co., Ltd. (hereinafter referred to as "Sai'er Biopharmaceutical"), has recently received the "Acceptance Notice" for the marketing application of Dapagliflozin Active Pharmaceutical Ingredient issued by the National Medical Products Administration. Dapagliflozin is a new type of oral hypoglycemic agent, originally developed by Bristol-Myers Squibb, which later licensed the intellectual property and Global production and sales rights to AstraZeneca. In 2012, Dapagliflozin was approved by the European EMA for the treatment of type 2 diabetes, becoming the first drug in the SGLT-2 class approved globally; in 2014, it was approved in the USA.
Science Sun Pharmaceutical's Unit Completes License Amendment
Express News | Beijing Science Sun Pharmaceutical: The subsidiary's pharmaceutical production license change has been approved.
Saisheng Pharmaceutical: Report for the third quarter of 2024
Beijing Science Sun Pharmaceutical (300485.SZ) released its performance for the first three quarters, with a net loss of 98.1982 million yuan.
Beijing Science Sun Pharmaceutical (300485.SZ) released the third quarter report for 2024, with the company's revenue for the first three quarters reaching 3...
Beijing Science Sun Pharmaceutical (300485.SZ): a net loss of 98.1982 million yuan in the first three quarters.
On October 24th, Gelonghui reported that Beijing Science Sun Pharmaceutical (300485.SZ) released the third quarter report of 2024. In the first three quarters of 2024, the company achieved revenue of 0.323 billion yuan, a decrease of 18.01% year-on-year; the net loss attributable to the shareholders of the listed company was 98.1982 million yuan, a decrease of 149.97% year-on-year; the net profit after deducting non-recurring gains and losses was 17.5475 million yuan, a decrease of 21.27% year-on-year; basic earnings per share was -0.20 yuan per share.
No Data
